Effects of common antihypertensive drugs on aldosterone concentration/renin concentration results

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200056129

Enrollment

Unknown

Registered

2022-02-01

Start date

2021-10-26

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

ß receptor blocker group:ß receptor blocker was discontinued

ACEI (or ARB) group:Stop ACEI (or ARB)

CCB group:Stop CCB

A+C (ACEI+CCB, ARB+CCB) group:Stop A + C (ACEI + CCB, ARB + CCB)

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. 18 years = 140/90 mmHg); 3. Take A, B, C and A + C antihypertensive drugs at least three months before enrollment; 4. Patients informed and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Women during pregnancy or lactation; 2. Patients with antihypertensive drugs and diuretics other than the above drugs; 3. Patients with acute hypertension or severe cardiovascular and cerebrovascular diseases that are not suitable for elution; 4. Excluding patients with secondary aldosteronism such as renal artery stenosis or renal insufficiency.

Design outcomes

Primary

Measure	Time frame
plasma aldosterone concentration;plasma renin concentration;Blood cortisol concentration;	—

Countries

China

Contacts

Public ContactXiaohui Wang

Fuwai Central China Cardiovascular Hospital

135255549237@126.com+86 13525549237

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026